View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsCore Scientific 과거 순이익 실적과거 기준 점검 0/6Core Scientific 의 수입은 연평균 -126%의 비율로 감소해 온 반면, IT 산업은 연평균 7.1%의 비율로 증가했습니다. 매출은 연평균 74.1%의 비율로 증가해 왔습니다.핵심 정보-125.96%순이익 성장률-115.97%주당순이익(EPS) 성장률IT 산업 성장률13.97%매출 성장률74.15%자기자본이익률n/a순이익률-335.20%최근 순이익 업데이트31 Dec 2022최근 과거 실적 업데이트공지 • Oct 31Core Scientific, Inc. to Report Q3, 2024 Results on Nov 06, 2024Core Scientific, Inc. announced that they will report Q3, 2024 results After-Market on Nov 06, 2024공지 • Aug 01Core Scientific, Inc. to Report Q2, 2024 Results on Aug 07, 2024Core Scientific, Inc. announced that they will report Q2, 2024 results After-Market on Aug 07, 2024공지 • May 05Core Scientific, Inc. to Report Q1, 2024 Results on May 08, 2024Core Scientific, Inc. announced that they will report Q1, 2024 results After-Market on May 08, 2024공지 • Mar 06Core Scientific, Inc. to Report Fiscal Year 2023 Results on Mar 12, 2024Core Scientific, Inc. announced that they will report fiscal year 2023 results After-Market on Mar 12, 2024Reported Earnings • Aug 13Second quarter 2022 earnings released: US$2.65 loss per share (vs US$0.034 loss in 2Q 2021)Second quarter 2022 results: US$2.65 loss per share (down from US$0.034 loss in 2Q 2021). Revenue: US$164.0m (up 118% from 2Q 2021). Net loss: US$861.7m (loss widened US$858.3m from 2Q 2021). Over the next year, revenue is forecast to grow 14%, compared to a 17% growth forecast for the industry in Germany.공지 • Aug 12Core Scientific, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2022Core Scientific, Inc. announced impairment charges for the second quarter ended June 30, 2022. The company has announced impairment of goodwill of $840,000.모든 업데이트 보기Recent updates공지 • Oct 31Core Scientific, Inc. to Report Q3, 2024 Results on Nov 06, 2024Core Scientific, Inc. announced that they will report Q3, 2024 results After-Market on Nov 06, 2024공지 • Aug 01Core Scientific, Inc. to Report Q2, 2024 Results on Aug 07, 2024Core Scientific, Inc. announced that they will report Q2, 2024 results After-Market on Aug 07, 2024공지 • Jun 08CoreWeave, Inc. cancelled the acquisition of Core Scientific, Inc. (NasdaqGS:CORZ).CoreWeave, Inc. made an unsolicited non-binding proposal to acquire Core Scientific, Inc. (NasdaqGS:CORZ) for $1.2 billion on June 3, 2024. CoreWeave made a proposal to acquire all of the outstanding shares of Core Scientific on a fully diluted basis for $5.75 per share in cash. The Board of Directors of Core Scientific determined that the CoreWeave proposal significantly undervalues the Company and is not in the best interests of Core Scientific and its shareholders. Moelis & Company LLC is acting as financial advisor to Core Scientific. Sidley Austin LLP is acting as legal advisor to Core Scientific. CoreWeave, Inc. cancelled the acquisition of Core Scientific, Inc. (NasdaqGS:CORZ) on June 6, 2024.공지 • May 05Core Scientific, Inc. to Report Q1, 2024 Results on May 08, 2024Core Scientific, Inc. announced that they will report Q1, 2024 results After-Market on May 08, 2024공지 • Mar 06Core Scientific, Inc. to Report Fiscal Year 2023 Results on Mar 12, 2024Core Scientific, Inc. announced that they will report fiscal year 2023 results After-Market on Mar 12, 2024공지 • Jan 25+ 1 more updateCore Scientific, Inc. Emerged from BankruptcyCore Scientific, Inc. emerged from its Chapter 11 bankruptcy as its modified fourth amended plan of reorganization became effective on January 23, 2024. Core Scientific, Inc. had filed its modified fourth amended plan of reorganization in the Court on January 15, 2024.공지 • Jan 24+ 1 more updateCore Scientific, Inc. Com Deleted from OTC EquityCore Scientific, Inc. Com has been deleted from OTC Equity effective January 23, 2024, due to Bankruptcy Plan Effective Shares Cancelled /Distribution.공지 • Jan 18Modified Fourth Amended Joint Reorganization Plan and Disclosure Statement Approved for Core Scientific, Inc.The US Bankruptcy Court approved the modified fourth amended joint plan of reorganization and Disclosure Statement of Core Scientific, Inc. on January 16, 2024. The debtor has filed its modified fourth amended joint plan in the Court on January 15, 2024. As per the amended plan, administrative expense claims, professional fee claims, priority non-tax claim, priority tax claims, DIP claims of $105 million, shall be paid in full in cash. April convertible notes secured claims of $350 million shall receive its pro rata share of the new secured notes, pro rata reduced convertible notes share of (a) the new secured convertible notes and (b) the convertible noteholders equity distribution, (iii) such holder’s pro rata convertible notes equity distribution share of the contingent payment obligations, and (iv) such holder’s pro rata total convertible notes. August convertible notes secured claims of $360 million shall receive its pro rata share of reduced convertible notes share of (a) the new secured convertible notes and (b) the convertible noteholders equity distribution, (ii) such holder’s pro rata convertible notes equity distribution share of the contingent payment obligations, and (iii) such holder’s pro rata total convertible notes share of (a) the ERO shortfall equity distribution (if any), (b) the first incremental convertible noteholders equity distribution (if any), and (c) the second incremental convertible noteholders equity distribution. Miner equipment lender secured claims of $253.7 million shall receive such holder’s applicable miner equipment lender takeback debt. Other secured claims of $20.6 million shall be reinstated. M&M lien secured claims are of $0. Secured mortgage claims of $0.81 million shall receive such Holder’s applicable Mortgage Takeback Debt. General unsecured claims of $89.6 million shall receive its pro rata share of new common interests with a value, based on plan value, equal 100% of such holder’s allowed general unsecured claim, (y) such holder’s pro rata share of the GUC settlement additional equity distribution amount, and (z) such holder’s pro rata share of the GUC contingent payment obligations. Convenience claims of $0.13 million shall be paid in full in cash. Intercompany claims and intercompany interests shall be reinstated. Section 510(b) claims are estimated to be $0. Existing common interests shall receive its pro rata share of equity share of the residual equity pool, (ii) such holder’s pro rata equity share of the new warrants, and (iii) the right to participate in the rights offering in accordance with the rights offering procedures. The plan shall be funded through cash, new April secured notes, new August secured notes, first-lien delayed draw term loans, M&M lien takeback debt, miner equipment lender takeback debt, mortgage takeback debt, and common stock.공지 • Jan 09Core Scientific, Inc. has completed a Follow-on Equity Offering in the amount of $55 million.Core Scientific, Inc. has completed a Follow-on Equity Offering in the amount of $55 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: Rights Offering공지 • Dec 28Amended Reorganization Plan Filed by Core Scientific, Inc.Core Scientific, Inc., along with its affiliates, filed fourth amended joint plan of reorganization with related disclosure statement in the US Bankruptcy Court on December 26, 2023. As per the plan filed, Convenience Claims shall be paid in cash.공지 • Nov 22Core Scientific, Inc. has filed a Follow-on Equity Offering in the amount of $55 million.Core Scientific, Inc. has filed a Follow-on Equity Offering in the amount of $55 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: Rights Offering공지 • Sep 23Core Scientific, Inc. announced that it expects to receive $53.9 million in funding from Bitmain Technologies LimitedCore Scientific, Inc. announced a private placement of common shares for the gross proceeds of $53.9 million on September 22, 2023. The transaction will include participation from new investor Bitmain Technologies Limited.공지 • Aug 05Core Scientific, Inc. Appoints Adam Sullivan as Chief Executive OfficerCore Scientific, Inc. announced Adam Sullivan has been appointed Chief Executive Officer. Adam assumes the CEO position after serving as President of Core Scientific. Mike Levitt will continue as the Chairman of the Board of Directors. Since joining the company, Adam has redesigned Cores organizational structure, enhanced the Companys restructuring efforts and improved communication and collaboration across functions. Adams expertise and strategic vision for the future of Core Scientific has resulted in increased engagement across the team. Adam Sullivan has more than a decade of experience in financial services, with a focus on investment banking in the digital assets and infrastructure space. His expertise spans strategy development, corporate finance and M&A. Prior to joining Core Scientific as President in 2023, Adam served as a Managing Director and Head of Digital Assets and Infrastructure at XMS Capital Partners. In his role at XMS, Adam established himself as one of the key facilitators for M&A and capital raises in the crypto mining industry, overseeing more than $5 billion of transactions, including Core Scientifics business combination with Power &Digital Infrastructure Acquisition Corp. in 2021. He previously served at Indian Wells Capital Management and M&T Bank. Adam received his Bachelor of Arts in Financial Economics from the University of Rochester.공지 • May 18Core Scientific, Inc. Appoints Adam Sullivan as PresidentOn April 20, 2023, the board of directors of Core Scientific, Inc. appointed Adam Sullivan as president, effective May 15, 2023. Mr. Sullivan will report to Mike Levitt, the Company’s Chief Executive Officer, and will oversee financial and strategic matters, including assisting with the negotiation of the Company’s reorganization plan. In connection with the appointment of Mr. Sullivan, Todd M. DuChene will continue to serve as the Company’s Chief Legal Officer while also assuming the new role of Chief Administrative Officer. Prior to his appointment as President, Mr. Sullivan, age 32, was Managing Director and Head of Digital Assets and Infrastructure Group at XMS Capital Partners, where he oversaw over $5 billion of transactions. Mr. Sullivan joined XMS Capital Partners in 2017. Mr. Sullivan also represented the Power and Digital Infrastructure Acquisition Corporation in its acquisition of Core Scientific Holding Company, the Company’s predecessor, in 2021.공지 • May 11Core Scientific, Inc. announced delayed 10-Q filingOn 05/10/2023, Core Scientific, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공지 • Jan 04Core Scientific, Inc.(OTCPK:CORZ.Q) dropped from NASDAQ Composite IndexCore Scientific, Inc. has been removed from NASDAQ Composite Index .공지 • Dec 28Core Scientific's Common Stock to Be Delisted from NasdaqOn December 22, 2022, Core Scientific, Inc. received written notice (the "Delisting Notice") from the staff of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, as a result of the Chapter 11 Cases and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq had determined that the Company's common stock (the "Securities") will be delisted from Nasdaq. Trading of the Securities will be suspended at the opening of business on January 3, 2023 and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Securities from listing and registration on Nasdaq. In the Delisting Notice, the staff of Nasdaq referenced concerns about the Company's ability to sustain compliance with all requirements for continued listing on Nasdaq and public interest concerns related to the Chapter 11 Cases. The Delisting Notice also indicates that the Company may appeal Nasdaq's determination pursuant to procedures set in Nasdaq Listing Rule 5800 Series. The Company is currently evaluating the options available to it in connection with Delisting Notice.공지 • Dec 22Core Scientific, Inc. Filed for BankruptcyCore Scientific, Inc., along with its ten affiliates filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of Texas on December 21, 2022. The debtor listed both its assets and liabilities in the range of $1 billion to $10 billion. The debtor is represented by Alfredo R Perez of Weil, Gotshal & Manges LLP as its legal counsel. The debtor also hired PJT Partners LP as its investment banker and AlixPartners, LLP as its financial advisor. Stretto Inc. has been appointed as claims and noticing agent to the debtor.공지 • Dec 17Core Scientific Receives A Written Notice from the Listing Qualifications Staff of Nasdaq Regarding Minimum Bid Price RequirementOn December 13, 2022, Core Scientific, Inc. ("the Company") received a written notice (the Notice") from the Listing Qualifications Staff of The Nasdaq Stock Market ("Nasdaq") notifying the Company that, because theclosing bid price for the Company's common stock, par value $0.0001 per share (the Common Stock"), has fallen below $1.00 per share for 30 consecutive business days, the Company no longer meets the minimum bid price requirement for continued inclusion on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the Bid Price Requirement"). This Notice has no immediate effect on the listing of the Company's Common Stock. Pursuant to Nasdaq Marketplace Rule 5810(c)(3)(A), the Company has an initial compliance period of 180 calendar days, or until June 12, 2023, to regain compliance with the Minimum Bid Price Requirement. If at any time before June 12, 2023, the closing bid price of the Common Stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation stating that the Company has achieved compliance with the Minimum Bid Price Requirement. If the Company's Common Stock does not regain compliance with the Minimum Bid Price Requirement during this initial 180-day grace period, the Company may be eligible for an additional grace period of 180 calendar days provided that (i) the Company satisfies Nasdaq's continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the Minimum Bid Price Requirement; and (ii) the Company provides written notice to Nasdaq of its intention to cure the delinquency during the second grace period. The Company intends to monitor the closing bid price of its Common Stock and may, if appropriate, consider available options to regain compliance with the Bid Price Requirement. There can be no assurance that the Company will be able to regain compliance with the Bid Price Requirement or that Nasdaq will grant the Company a further extension of time to regain compliance, if applicable.공지 • Nov 30Stacie Olivares Resigns as A Director of Core Scientific, IncOn November 21, 2022, Stacie Olivares informed the Board of Directors of Core Scientific, Inc. of her intention to resign as a director of the Board and any committees thereof effective November 21, 2022. Ms. Olivares’ resignation was not due to any disagreement with the Board, the Company or management on any matter relating to the Company's operations, policies or practices.공지 • Nov 16Core Scientific, Inc. Appoints Todd Duchene as President and Chief Legal Officer, Effective November 14, 2022On November 9, 2022, the board of directors of Core Scientific, Inc. appointed Todd DuChene to serve as the Company’s President and Chief Legal Officer, effective November 14, 2022. Mr. DuChene, age 59, has served as the Company’s Executive Vice President, General Counsel, Chief Compliance Officer and Secretary since January 2022. He had served as General Counsel and Secretary of Core Scientific Holding Co. from April 2019 until Legacy Core’s merger with Power & Digital Infrastructure Acquisition Corp. Prior to joining Legacy Core, Mr. DuChene served as Senior Vice President, General Counsel and Secretary and Chief Compliance Officer for FLIR Systems, Inc., an industrial and military technology company, from September 2014 to April 2019.공지 • Nov 15+ 1 more updateCore Scientific, Inc. announced delayed 10-Q filingOn 11/14/2022, Core Scientific, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.공지 • Oct 28+ 2 more updatesCore Scientific, Inc Contemplates BankruptcyCore Scientific, Inc is contemplating filing for bankruptcy, as of October 27, 2022. According to company press release, Company said that as it is unable to satisfy its debt obligations, it will have a material adverse effect on its financial condition and results of operations, which may result in bankruptcy or insolvency.공지 • Oct 27Core Scientific, Inc. Announces Management ChangesCore Scientific, Inc. announced that on October 19, 2022, the Company eliminated the position held by Brian Neville, the Company’s Controller and Chief Accounting Officer. Denise Sterling, the Company’s Executive Vice President and Chief Financial Officer, will serve as principal accounting officer, effective immediately, in addition to her existing responsibilities. Ms. Sterling has served as the Company’s Chief Financial Officer since April 4, 2022, and prior to that she served as the Company’s Senior Vice President of Finance from May 2021.공지 • Aug 17Core Scientific, Inc. announced delayed 10-Q filingOn 08/16/2022, Core Scientific, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.Reported Earnings • Aug 13Second quarter 2022 earnings released: US$2.65 loss per share (vs US$0.034 loss in 2Q 2021)Second quarter 2022 results: US$2.65 loss per share (down from US$0.034 loss in 2Q 2021). Revenue: US$164.0m (up 118% from 2Q 2021). Net loss: US$861.7m (loss widened US$858.3m from 2Q 2021). Over the next year, revenue is forecast to grow 14%, compared to a 17% growth forecast for the industry in Germany.공지 • Aug 12Core Scientific, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2022Core Scientific, Inc. announced impairment charges for the second quarter ended June 30, 2022. The company has announced impairment of goodwill of $840,000.공지 • Jul 22Core Scientific, Inc. announced that it expects to receive $100 million in funding from B. Riley Principal Capital II, LLCCore Scientific, Inc. entered into a common stock purchase agreement with B. Riley Principal Capital II, LLC for gross proceeds of $100 million on July 20, 2022. The company issued purchase notices to the investor for over a 24-month period, and also issued 573,381 shares to the investor as consideration for its purchase under the purchase agreement. The company reimbursed $75,000 of reasonable legal fees and disbursements of investor's legal counsel in connection with the transactions. The securities issued will be made in reliance upon the provisions of Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated by the commission under the Securities Act.공지 • Jul 06Core Scientific, Inc. to Report Q2, 2022 Results on Aug 11, 2022Core Scientific, Inc. announced that they will report Q2, 2022 results on Aug 11, 2022Recent Insider Transactions • Jun 03Co-Founder recently sold €8.4m worth of stockOn the 1st of June, Darin Feinstein sold around 3m shares on-market at roughly €3.25 per share. This was the largest sale by an insider in the last 3 months. This was Darin's only on-market trade for the last 12 months.공지 • May 13Core Scientific, Inc. Provides Operating Guidance for the Year 2022Core Scientific, Inc. provided operating guidance for the year 2022. For 2022, the Company now expects to achieve total hashrate of between 30 EH/s and 32 EH/s, with total power of approximately 1 GW.Valuation Update With 7 Day Price Move • May 11Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €4.30, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 22x in the IT industry in Germany.Reported Earnings • Apr 27Full year 2021 earnings released: EPS: US$0.36 (vs US$0.23 loss in FY 2020)Full year 2021 results: EPS: US$0.36 (up from US$0.23 loss in FY 2020). Revenue: US$544.5m (up US$484.2m from FY 2020). Net income: US$47.3m (up US$70.0m from FY 2020). Profit margin: 8.7% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 93%, compared to a 20% growth forecast for the industry in Germany.Valuation Update With 7 Day Price Move • Apr 23Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to €5.90, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 26x in the IT industry in Germany.공지 • Apr 09+ 1 more updateCore Scientific, Inc. announced that it expects to receive $75 million in funding from B. Riley Commercial Capital, LLCCore Scientific, Inc. announced that it has entered into two bridge promissory notes with an affiliate of B. Riley Commercial Capital, LLC for gross proceeds of $75,000,000 on April 7, 2022. The two notes are in an aggregate principal amount of $60,000,000 and $15,000,000 respectively. The notes mature on December 7, 2022, bear interest at a rate of 7% per annum and amortize in equal monthly installments starting on August 1, 2022. The notes are unsecured and not guaranteed by any subsidiary of the company.공지 • Apr 06Core Scientific, Inc. Announces CFO ChangesCore Scientific, Inc. announced that Denise Sterling, Senior Vice President of Finance, has been appointed to the role of Chief Financial Officer and will be moving to the Austin, TX headquarters later 2022. Former CFO Michael Trzupek will leave the company to pursue new opportunities after a transition period. Denise Sterling joined Core Scientific in May 2021, built and led the Company’s Financial Planning and Analysis function and developed financial processes and procedures supporting the Company’s entry into the public equity markets.Prior to joining Core Scientific, Mrs. Sterling served as Senior Vice President of Finance and FP&A for Oportun.Reported Earnings • Mar 31Full year 2021 earnings released: EPS: US$365 (vs US$230 loss in FY 2020)Full year 2021 results: EPS: US$365 (up from US$230 loss in FY 2020). Revenue: US$544.5m (up US$484.2m from FY 2020). Net income: US$47.3m (up US$70.0m from FY 2020). Profit margin: 8.7% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 101%, compared to a 17% growth forecast for the industry in Germany.Board Change • Mar 29Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Co-Founder, Co-Chairman & CEO Mike Levitt was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.매출 및 비용 세부 내역Core Scientific가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이DB:7ZD0 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Dec 22640-2,1462242730 Sep 22821-1,6511992830 Jun 22771-1,2331942331 Mar 22683-4261021031 Dec 215444765830 Sep 21266-1653530 Jun 21163-120531 Mar 2194-616531 Dec 2060-2316531 Dec 1960-12175양질의 수익: 7ZD0 은(는) 현재 수익성이 없습니다.이익 마진 증가: 7ZD0는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 지난 5년 동안 7ZD0의 연간 수익 성장률이 양(+)이었는지 판단하기에 데이터가 부족합니다.성장 가속화: 현재 수익성이 없어 지난 1년간 7ZD0의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: 7ZD0은 수익성이 없어 지난 해 수익 성장률을 IT 업계(-12%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: 7ZD0의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YSoftware 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/04/17 13:03종가2023/01/18 00:00수익2022/12/31연간 수익2022/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Core Scientific, Inc.는 21명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Ramsey El-AssalBarclaysGautam ChhuganiBernsteinNicholas GilesB. Riley Securities, Inc.18명의 분석가 더 보기
공지 • Oct 31Core Scientific, Inc. to Report Q3, 2024 Results on Nov 06, 2024Core Scientific, Inc. announced that they will report Q3, 2024 results After-Market on Nov 06, 2024
공지 • Aug 01Core Scientific, Inc. to Report Q2, 2024 Results on Aug 07, 2024Core Scientific, Inc. announced that they will report Q2, 2024 results After-Market on Aug 07, 2024
공지 • May 05Core Scientific, Inc. to Report Q1, 2024 Results on May 08, 2024Core Scientific, Inc. announced that they will report Q1, 2024 results After-Market on May 08, 2024
공지 • Mar 06Core Scientific, Inc. to Report Fiscal Year 2023 Results on Mar 12, 2024Core Scientific, Inc. announced that they will report fiscal year 2023 results After-Market on Mar 12, 2024
Reported Earnings • Aug 13Second quarter 2022 earnings released: US$2.65 loss per share (vs US$0.034 loss in 2Q 2021)Second quarter 2022 results: US$2.65 loss per share (down from US$0.034 loss in 2Q 2021). Revenue: US$164.0m (up 118% from 2Q 2021). Net loss: US$861.7m (loss widened US$858.3m from 2Q 2021). Over the next year, revenue is forecast to grow 14%, compared to a 17% growth forecast for the industry in Germany.
공지 • Aug 12Core Scientific, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2022Core Scientific, Inc. announced impairment charges for the second quarter ended June 30, 2022. The company has announced impairment of goodwill of $840,000.
공지 • Oct 31Core Scientific, Inc. to Report Q3, 2024 Results on Nov 06, 2024Core Scientific, Inc. announced that they will report Q3, 2024 results After-Market on Nov 06, 2024
공지 • Aug 01Core Scientific, Inc. to Report Q2, 2024 Results on Aug 07, 2024Core Scientific, Inc. announced that they will report Q2, 2024 results After-Market on Aug 07, 2024
공지 • Jun 08CoreWeave, Inc. cancelled the acquisition of Core Scientific, Inc. (NasdaqGS:CORZ).CoreWeave, Inc. made an unsolicited non-binding proposal to acquire Core Scientific, Inc. (NasdaqGS:CORZ) for $1.2 billion on June 3, 2024. CoreWeave made a proposal to acquire all of the outstanding shares of Core Scientific on a fully diluted basis for $5.75 per share in cash. The Board of Directors of Core Scientific determined that the CoreWeave proposal significantly undervalues the Company and is not in the best interests of Core Scientific and its shareholders. Moelis & Company LLC is acting as financial advisor to Core Scientific. Sidley Austin LLP is acting as legal advisor to Core Scientific. CoreWeave, Inc. cancelled the acquisition of Core Scientific, Inc. (NasdaqGS:CORZ) on June 6, 2024.
공지 • May 05Core Scientific, Inc. to Report Q1, 2024 Results on May 08, 2024Core Scientific, Inc. announced that they will report Q1, 2024 results After-Market on May 08, 2024
공지 • Mar 06Core Scientific, Inc. to Report Fiscal Year 2023 Results on Mar 12, 2024Core Scientific, Inc. announced that they will report fiscal year 2023 results After-Market on Mar 12, 2024
공지 • Jan 25+ 1 more updateCore Scientific, Inc. Emerged from BankruptcyCore Scientific, Inc. emerged from its Chapter 11 bankruptcy as its modified fourth amended plan of reorganization became effective on January 23, 2024. Core Scientific, Inc. had filed its modified fourth amended plan of reorganization in the Court on January 15, 2024.
공지 • Jan 24+ 1 more updateCore Scientific, Inc. Com Deleted from OTC EquityCore Scientific, Inc. Com has been deleted from OTC Equity effective January 23, 2024, due to Bankruptcy Plan Effective Shares Cancelled /Distribution.
공지 • Jan 18Modified Fourth Amended Joint Reorganization Plan and Disclosure Statement Approved for Core Scientific, Inc.The US Bankruptcy Court approved the modified fourth amended joint plan of reorganization and Disclosure Statement of Core Scientific, Inc. on January 16, 2024. The debtor has filed its modified fourth amended joint plan in the Court on January 15, 2024. As per the amended plan, administrative expense claims, professional fee claims, priority non-tax claim, priority tax claims, DIP claims of $105 million, shall be paid in full in cash. April convertible notes secured claims of $350 million shall receive its pro rata share of the new secured notes, pro rata reduced convertible notes share of (a) the new secured convertible notes and (b) the convertible noteholders equity distribution, (iii) such holder’s pro rata convertible notes equity distribution share of the contingent payment obligations, and (iv) such holder’s pro rata total convertible notes. August convertible notes secured claims of $360 million shall receive its pro rata share of reduced convertible notes share of (a) the new secured convertible notes and (b) the convertible noteholders equity distribution, (ii) such holder’s pro rata convertible notes equity distribution share of the contingent payment obligations, and (iii) such holder’s pro rata total convertible notes share of (a) the ERO shortfall equity distribution (if any), (b) the first incremental convertible noteholders equity distribution (if any), and (c) the second incremental convertible noteholders equity distribution. Miner equipment lender secured claims of $253.7 million shall receive such holder’s applicable miner equipment lender takeback debt. Other secured claims of $20.6 million shall be reinstated. M&M lien secured claims are of $0. Secured mortgage claims of $0.81 million shall receive such Holder’s applicable Mortgage Takeback Debt. General unsecured claims of $89.6 million shall receive its pro rata share of new common interests with a value, based on plan value, equal 100% of such holder’s allowed general unsecured claim, (y) such holder’s pro rata share of the GUC settlement additional equity distribution amount, and (z) such holder’s pro rata share of the GUC contingent payment obligations. Convenience claims of $0.13 million shall be paid in full in cash. Intercompany claims and intercompany interests shall be reinstated. Section 510(b) claims are estimated to be $0. Existing common interests shall receive its pro rata share of equity share of the residual equity pool, (ii) such holder’s pro rata equity share of the new warrants, and (iii) the right to participate in the rights offering in accordance with the rights offering procedures. The plan shall be funded through cash, new April secured notes, new August secured notes, first-lien delayed draw term loans, M&M lien takeback debt, miner equipment lender takeback debt, mortgage takeback debt, and common stock.
공지 • Jan 09Core Scientific, Inc. has completed a Follow-on Equity Offering in the amount of $55 million.Core Scientific, Inc. has completed a Follow-on Equity Offering in the amount of $55 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: Rights Offering
공지 • Dec 28Amended Reorganization Plan Filed by Core Scientific, Inc.Core Scientific, Inc., along with its affiliates, filed fourth amended joint plan of reorganization with related disclosure statement in the US Bankruptcy Court on December 26, 2023. As per the plan filed, Convenience Claims shall be paid in cash.
공지 • Nov 22Core Scientific, Inc. has filed a Follow-on Equity Offering in the amount of $55 million.Core Scientific, Inc. has filed a Follow-on Equity Offering in the amount of $55 million. Security Name: Common Stock Security Type: Common Stock Transaction Features: Rights Offering
공지 • Sep 23Core Scientific, Inc. announced that it expects to receive $53.9 million in funding from Bitmain Technologies LimitedCore Scientific, Inc. announced a private placement of common shares for the gross proceeds of $53.9 million on September 22, 2023. The transaction will include participation from new investor Bitmain Technologies Limited.
공지 • Aug 05Core Scientific, Inc. Appoints Adam Sullivan as Chief Executive OfficerCore Scientific, Inc. announced Adam Sullivan has been appointed Chief Executive Officer. Adam assumes the CEO position after serving as President of Core Scientific. Mike Levitt will continue as the Chairman of the Board of Directors. Since joining the company, Adam has redesigned Cores organizational structure, enhanced the Companys restructuring efforts and improved communication and collaboration across functions. Adams expertise and strategic vision for the future of Core Scientific has resulted in increased engagement across the team. Adam Sullivan has more than a decade of experience in financial services, with a focus on investment banking in the digital assets and infrastructure space. His expertise spans strategy development, corporate finance and M&A. Prior to joining Core Scientific as President in 2023, Adam served as a Managing Director and Head of Digital Assets and Infrastructure at XMS Capital Partners. In his role at XMS, Adam established himself as one of the key facilitators for M&A and capital raises in the crypto mining industry, overseeing more than $5 billion of transactions, including Core Scientifics business combination with Power &Digital Infrastructure Acquisition Corp. in 2021. He previously served at Indian Wells Capital Management and M&T Bank. Adam received his Bachelor of Arts in Financial Economics from the University of Rochester.
공지 • May 18Core Scientific, Inc. Appoints Adam Sullivan as PresidentOn April 20, 2023, the board of directors of Core Scientific, Inc. appointed Adam Sullivan as president, effective May 15, 2023. Mr. Sullivan will report to Mike Levitt, the Company’s Chief Executive Officer, and will oversee financial and strategic matters, including assisting with the negotiation of the Company’s reorganization plan. In connection with the appointment of Mr. Sullivan, Todd M. DuChene will continue to serve as the Company’s Chief Legal Officer while also assuming the new role of Chief Administrative Officer. Prior to his appointment as President, Mr. Sullivan, age 32, was Managing Director and Head of Digital Assets and Infrastructure Group at XMS Capital Partners, where he oversaw over $5 billion of transactions. Mr. Sullivan joined XMS Capital Partners in 2017. Mr. Sullivan also represented the Power and Digital Infrastructure Acquisition Corporation in its acquisition of Core Scientific Holding Company, the Company’s predecessor, in 2021.
공지 • May 11Core Scientific, Inc. announced delayed 10-Q filingOn 05/10/2023, Core Scientific, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공지 • Jan 04Core Scientific, Inc.(OTCPK:CORZ.Q) dropped from NASDAQ Composite IndexCore Scientific, Inc. has been removed from NASDAQ Composite Index .
공지 • Dec 28Core Scientific's Common Stock to Be Delisted from NasdaqOn December 22, 2022, Core Scientific, Inc. received written notice (the "Delisting Notice") from the staff of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that, as a result of the Chapter 11 Cases and in accordance with Nasdaq Listing Rules 5101, 5110(b) and IM-5101-1, the staff of Nasdaq had determined that the Company's common stock (the "Securities") will be delisted from Nasdaq. Trading of the Securities will be suspended at the opening of business on January 3, 2023 and a Form 25-NSE will be filed with the Securities and Exchange Commission, which will remove the Securities from listing and registration on Nasdaq. In the Delisting Notice, the staff of Nasdaq referenced concerns about the Company's ability to sustain compliance with all requirements for continued listing on Nasdaq and public interest concerns related to the Chapter 11 Cases. The Delisting Notice also indicates that the Company may appeal Nasdaq's determination pursuant to procedures set in Nasdaq Listing Rule 5800 Series. The Company is currently evaluating the options available to it in connection with Delisting Notice.
공지 • Dec 22Core Scientific, Inc. Filed for BankruptcyCore Scientific, Inc., along with its ten affiliates filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of Texas on December 21, 2022. The debtor listed both its assets and liabilities in the range of $1 billion to $10 billion. The debtor is represented by Alfredo R Perez of Weil, Gotshal & Manges LLP as its legal counsel. The debtor also hired PJT Partners LP as its investment banker and AlixPartners, LLP as its financial advisor. Stretto Inc. has been appointed as claims and noticing agent to the debtor.
공지 • Dec 17Core Scientific Receives A Written Notice from the Listing Qualifications Staff of Nasdaq Regarding Minimum Bid Price RequirementOn December 13, 2022, Core Scientific, Inc. ("the Company") received a written notice (the Notice") from the Listing Qualifications Staff of The Nasdaq Stock Market ("Nasdaq") notifying the Company that, because theclosing bid price for the Company's common stock, par value $0.0001 per share (the Common Stock"), has fallen below $1.00 per share for 30 consecutive business days, the Company no longer meets the minimum bid price requirement for continued inclusion on The Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the Bid Price Requirement"). This Notice has no immediate effect on the listing of the Company's Common Stock. Pursuant to Nasdaq Marketplace Rule 5810(c)(3)(A), the Company has an initial compliance period of 180 calendar days, or until June 12, 2023, to regain compliance with the Minimum Bid Price Requirement. If at any time before June 12, 2023, the closing bid price of the Common Stock is at least $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will provide written confirmation stating that the Company has achieved compliance with the Minimum Bid Price Requirement. If the Company's Common Stock does not regain compliance with the Minimum Bid Price Requirement during this initial 180-day grace period, the Company may be eligible for an additional grace period of 180 calendar days provided that (i) the Company satisfies Nasdaq's continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the Minimum Bid Price Requirement; and (ii) the Company provides written notice to Nasdaq of its intention to cure the delinquency during the second grace period. The Company intends to monitor the closing bid price of its Common Stock and may, if appropriate, consider available options to regain compliance with the Bid Price Requirement. There can be no assurance that the Company will be able to regain compliance with the Bid Price Requirement or that Nasdaq will grant the Company a further extension of time to regain compliance, if applicable.
공지 • Nov 30Stacie Olivares Resigns as A Director of Core Scientific, IncOn November 21, 2022, Stacie Olivares informed the Board of Directors of Core Scientific, Inc. of her intention to resign as a director of the Board and any committees thereof effective November 21, 2022. Ms. Olivares’ resignation was not due to any disagreement with the Board, the Company or management on any matter relating to the Company's operations, policies or practices.
공지 • Nov 16Core Scientific, Inc. Appoints Todd Duchene as President and Chief Legal Officer, Effective November 14, 2022On November 9, 2022, the board of directors of Core Scientific, Inc. appointed Todd DuChene to serve as the Company’s President and Chief Legal Officer, effective November 14, 2022. Mr. DuChene, age 59, has served as the Company’s Executive Vice President, General Counsel, Chief Compliance Officer and Secretary since January 2022. He had served as General Counsel and Secretary of Core Scientific Holding Co. from April 2019 until Legacy Core’s merger with Power & Digital Infrastructure Acquisition Corp. Prior to joining Legacy Core, Mr. DuChene served as Senior Vice President, General Counsel and Secretary and Chief Compliance Officer for FLIR Systems, Inc., an industrial and military technology company, from September 2014 to April 2019.
공지 • Nov 15+ 1 more updateCore Scientific, Inc. announced delayed 10-Q filingOn 11/14/2022, Core Scientific, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
공지 • Oct 28+ 2 more updatesCore Scientific, Inc Contemplates BankruptcyCore Scientific, Inc is contemplating filing for bankruptcy, as of October 27, 2022. According to company press release, Company said that as it is unable to satisfy its debt obligations, it will have a material adverse effect on its financial condition and results of operations, which may result in bankruptcy or insolvency.
공지 • Oct 27Core Scientific, Inc. Announces Management ChangesCore Scientific, Inc. announced that on October 19, 2022, the Company eliminated the position held by Brian Neville, the Company’s Controller and Chief Accounting Officer. Denise Sterling, the Company’s Executive Vice President and Chief Financial Officer, will serve as principal accounting officer, effective immediately, in addition to her existing responsibilities. Ms. Sterling has served as the Company’s Chief Financial Officer since April 4, 2022, and prior to that she served as the Company’s Senior Vice President of Finance from May 2021.
공지 • Aug 17Core Scientific, Inc. announced delayed 10-Q filingOn 08/16/2022, Core Scientific, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Reported Earnings • Aug 13Second quarter 2022 earnings released: US$2.65 loss per share (vs US$0.034 loss in 2Q 2021)Second quarter 2022 results: US$2.65 loss per share (down from US$0.034 loss in 2Q 2021). Revenue: US$164.0m (up 118% from 2Q 2021). Net loss: US$861.7m (loss widened US$858.3m from 2Q 2021). Over the next year, revenue is forecast to grow 14%, compared to a 17% growth forecast for the industry in Germany.
공지 • Aug 12Core Scientific, Inc. Announces Impairment Charges for the Second Quarter Ended June 30, 2022Core Scientific, Inc. announced impairment charges for the second quarter ended June 30, 2022. The company has announced impairment of goodwill of $840,000.
공지 • Jul 22Core Scientific, Inc. announced that it expects to receive $100 million in funding from B. Riley Principal Capital II, LLCCore Scientific, Inc. entered into a common stock purchase agreement with B. Riley Principal Capital II, LLC for gross proceeds of $100 million on July 20, 2022. The company issued purchase notices to the investor for over a 24-month period, and also issued 573,381 shares to the investor as consideration for its purchase under the purchase agreement. The company reimbursed $75,000 of reasonable legal fees and disbursements of investor's legal counsel in connection with the transactions. The securities issued will be made in reliance upon the provisions of Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated by the commission under the Securities Act.
공지 • Jul 06Core Scientific, Inc. to Report Q2, 2022 Results on Aug 11, 2022Core Scientific, Inc. announced that they will report Q2, 2022 results on Aug 11, 2022
Recent Insider Transactions • Jun 03Co-Founder recently sold €8.4m worth of stockOn the 1st of June, Darin Feinstein sold around 3m shares on-market at roughly €3.25 per share. This was the largest sale by an insider in the last 3 months. This was Darin's only on-market trade for the last 12 months.
공지 • May 13Core Scientific, Inc. Provides Operating Guidance for the Year 2022Core Scientific, Inc. provided operating guidance for the year 2022. For 2022, the Company now expects to achieve total hashrate of between 30 EH/s and 32 EH/s, with total power of approximately 1 GW.
Valuation Update With 7 Day Price Move • May 11Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to €4.30, the stock trades at a forward P/E ratio of 6x. Average forward P/E is 22x in the IT industry in Germany.
Reported Earnings • Apr 27Full year 2021 earnings released: EPS: US$0.36 (vs US$0.23 loss in FY 2020)Full year 2021 results: EPS: US$0.36 (up from US$0.23 loss in FY 2020). Revenue: US$544.5m (up US$484.2m from FY 2020). Net income: US$47.3m (up US$70.0m from FY 2020). Profit margin: 8.7% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 93%, compared to a 20% growth forecast for the industry in Germany.
Valuation Update With 7 Day Price Move • Apr 23Investor sentiment deteriorated over the past weekAfter last week's 19% share price decline to €5.90, the stock trades at a forward P/E ratio of 9x. Average forward P/E is 26x in the IT industry in Germany.
공지 • Apr 09+ 1 more updateCore Scientific, Inc. announced that it expects to receive $75 million in funding from B. Riley Commercial Capital, LLCCore Scientific, Inc. announced that it has entered into two bridge promissory notes with an affiliate of B. Riley Commercial Capital, LLC for gross proceeds of $75,000,000 on April 7, 2022. The two notes are in an aggregate principal amount of $60,000,000 and $15,000,000 respectively. The notes mature on December 7, 2022, bear interest at a rate of 7% per annum and amortize in equal monthly installments starting on August 1, 2022. The notes are unsecured and not guaranteed by any subsidiary of the company.
공지 • Apr 06Core Scientific, Inc. Announces CFO ChangesCore Scientific, Inc. announced that Denise Sterling, Senior Vice President of Finance, has been appointed to the role of Chief Financial Officer and will be moving to the Austin, TX headquarters later 2022. Former CFO Michael Trzupek will leave the company to pursue new opportunities after a transition period. Denise Sterling joined Core Scientific in May 2021, built and led the Company’s Financial Planning and Analysis function and developed financial processes and procedures supporting the Company’s entry into the public equity markets.Prior to joining Core Scientific, Mrs. Sterling served as Senior Vice President of Finance and FP&A for Oportun.
Reported Earnings • Mar 31Full year 2021 earnings released: EPS: US$365 (vs US$230 loss in FY 2020)Full year 2021 results: EPS: US$365 (up from US$230 loss in FY 2020). Revenue: US$544.5m (up US$484.2m from FY 2020). Net income: US$47.3m (up US$70.0m from FY 2020). Profit margin: 8.7% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Over the next year, revenue is forecast to grow 101%, compared to a 17% growth forecast for the industry in Germany.
Board Change • Mar 29Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. Co-Founder, Co-Chairman & CEO Mike Levitt was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.